Key Messages to Investors

Please read our caution about Forward-Looking Statements in the Conditions of Use when using this information.

  • Creating a global leader in agriculture through acquisition of Monsanto
  • Proven integration/separation capabilities
  • Track record of delivering shareholder value through successful portfolio management
  • Mid-term aspirations emphasize growth and margin potential
  • Pharma launch products expected to drive growth; peak sales potential increased
    to >€10bn
  • Consumer health challenges addressed
  • Crop Science expected to benefit from cyclical market upswing and long-term
    GDP+ growth potential
  • Upcoming new product launches and life cycle management at Pharma expected to mitigate loss of exclusivity post 2023
  • Combined peak sales potential of key late-stage Pharma pipeline assets ≥€6bn
  • Consumer Health delivering steady stream of consumer-centric innovations
  • Strong R&D capabilities at combined Crop Science business*